These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 6433484)
1. Brain enzyme is the target of drug toxin. Lewin R Science; 1984 Sep; 225(4669):1460-2. PubMed ID: 6433484 [No Abstract] [Full Text] [Related]
2. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Singer TP; Castagnoli N; Ramsay RR; Trevor AJ J Neurochem; 1987 Jul; 49(1):1-8. PubMed ID: 3495634 [No Abstract] [Full Text] [Related]
3. Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism. Poirier J J Am Geriatr Soc; 1987 Jul; 35(7):660-8. PubMed ID: 3108351 [No Abstract] [Full Text] [Related]
4. The role of MAO in MPTP toxicity--a review. Glover V; Gibb C; Sandler M J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762 [TBL] [Abstract][Full Text] [Related]
5. MPTP effects on dopamine neurons. Kopin IJ Ann N Y Acad Sci; 1988; 537():451-61. PubMed ID: 3059935 [No Abstract] [Full Text] [Related]
6. Histochemical localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine oxidation in the mouse brain. Vincent SR Neuroscience; 1989; 28(1):189-99. PubMed ID: 2569695 [TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease: current view. Langston JW Am Fam Physician; 1987 Mar; 35(3):201-6. PubMed ID: 3103408 [TBL] [Abstract][Full Text] [Related]
8. Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. Da Prada M; Kettler R; Keller HH; Bonetti EP; Imhof R Adv Neurol; 1987; 45():175-8. PubMed ID: 2881442 [No Abstract] [Full Text] [Related]
9. High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase. Parsons B; Rainbow TC Eur J Pharmacol; 1984 Jul; 102(2):375-7. PubMed ID: 6332739 [No Abstract] [Full Text] [Related]
11. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Kalaria RN; Mitchell MJ; Harik SI Proc Natl Acad Sci U S A; 1987 May; 84(10):3521-5. PubMed ID: 3495000 [TBL] [Abstract][Full Text] [Related]
12. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs. Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564 [TBL] [Abstract][Full Text] [Related]
13. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. Snyder SH; D'Amato RJ Neurology; 1986 Feb; 36(2):250-8. PubMed ID: 3080696 [TBL] [Abstract][Full Text] [Related]
14. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs. Youngster SK; Nicklas WJ; Heikkila RE J Pharmacol Exp Ther; 1989 Jun; 249(3):829-35. PubMed ID: 2786565 [TBL] [Abstract][Full Text] [Related]
15. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals. Kopin IJ Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621 [No Abstract] [Full Text] [Related]
19. Similar distribution of monoamine oxidase (MAO) and parkinsonian toxin (MPTP) binding sites in human brain. Reznikoff G; Manaker S; Parsons B; Rhodes CH; Rainbow TC Neurology; 1985 Oct; 35(10):1415-9. PubMed ID: 3875804 [TBL] [Abstract][Full Text] [Related]
20. Chemical oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its in vivo metabolism in rat brain and liver. Arora PK; Riachi NJ; Harik SI; Sayre LM Biochem Biophys Res Commun; 1988 May; 152(3):1339-47. PubMed ID: 3259874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]